TerrAscend Corp (CSE: TER) announced this morning that it intends to raise US$20 million via a private placement to continue its capital projects in New Jersey, as well as to provide cash for a milestone payment due in January. The raise has received lead orders of US$15 million in relation to the financing, some of which comes from insiders of the issuer.
Under the terms of the financing, TerrAscend is looking to raise US$20 million via the issuance of shares at a price of C$2.45 per unit. Each unit is to contain a common share and a full warrant, with the warrant being valid for a period of 24 months with an exercise price of C$3.25. A total of 10.775 million units are expected to be issued in conjunction with the financing.
Proceeds raised will go towards construction of certain New Jersey assets, including a cultivation and processing facility. The funds will also be used to make a milestone cash payment due in January 2020 in relation to the acquisition of Ilera Healthcare. Whatever remains following these transactions will be put towards working capital and general corporate purposes.
Chairman Jason Wild, and Executive Chairman Jason Ackerman, along with Entourage Effect Capital, will be co-leading the financing round. The three parties have collectively committed to approximately US$15 million under the current financing.
TerrAscend last traded at $2.50 on the Canadian Securities Exchange.
Information for this briefing was found via Sedar and TerrAscend Corp. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
